Theragnostic Technologies, Inc.

Coram, NY 11727

SBIR Award Summary

Total Number of Awards 6
Total Value of Awards $2.15MM
First Award Date 09/25/13
Most Recent Award Date 09/01/17

Key Personnel

Last Name Name Awards Contact
Sitharaman Balaji Sitharaman 4 Message
TOUSSAINT JIMMY DEON TOUSSAINT 4
KRUG LAURIE T KRUG 1

6 Awards Won

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-16-302
Budget: 09/01/17 - 05/31/18

Abstract This SBIR phase 1 proposal is to demonstrate the pre-clinical safety and efficacy of a novel carbon-nanostructure-based X-ray computer tomography (CT) contrast agent (CA) for imaging and monitoring in patients with renal failure or at risk of contrast induced nephropathy (CIN). Routine contrast enhanced CT scans relays crucial informati...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-16-302
Budget: 05/16/17 - 05/31/18

Abstract This SBIR phase 1 proposal is to demonstrate the pre-clinical safety and efficacy of a novel carbon-nanostructure-based X-ray computer tomography (CT) contrast agent (CA) for imaging and monitoring in patients with renal failure or at risk of contrast induced nephropathy (CIN). Routine contrast enhanced CT scans relays crucial informati...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-14-307
Budget: 04/01/17 - 09/30/17

Abstract Herpesviruses are chronic pathogens that infect for life; there is no cure. 50 years since the discovery of the first tumor virus, the herpesvirus Epstein-Barr virus (EBV), there exist no specific antivirals for EBV during its latency phase and there are no vaccines. The same holds true for most of the other eight human herpesviruses. ...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-14-071
Budget: 05/01/16 - 04/30/17

? DESCRIPTION (provided by applicant): This SBIR phase 2 project focuses on preclinical investigational new drug (IND) enabling studies of a novel high performance carbon nanostructure-based magnetic resonance imaging (MRI) contrast agent (CA) to be used to diagnose and monitor patients with renal failure. Every year, in the US, approximately ...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-14-071
Budget: 06/15/15 - 04/30/16

DESCRIPTION (provided by applicant): This SBIR phase 2 project focuses on preclinical investigational new drug (IND) enabling studies of a novel high performance carbon nanostructure-based magnetic resonance imaging (MRI) contrast agent (CA) to be used to diagnose and monitor patients with renal failure. Every year, in the US, approximately 20 m...

Phase 1 STTR

Agency: Department of Health & Human Services
Topic: PA-13-089
Budget: 09/25/13 - 08/31/14

Abstract This STTR phase 1 proposal investigates the safety and efficacy of a novel high-performance carbon nanostructure-based magnetic resonance imaging (MRI) contrast agent for the imaging and monitoring of patients with renal failure. Every year, in the US, approximately 20 million people are treated for mild to severe renal failure. A signi...